Engflag

Ranitidine Injection

Quick links to important sections

Ranitidine Injection

Ranitidine Injection_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ranitidine Injection

The foundational identity of Ranitidine Injection is best summarized by its key structural and functional properties, which define its therapeutic role as an acid reducer.

Property Description
Active Ingredient Ranitidine (as Ranitidine hydrochloride)
Form Sterile solution for injection
Pharmacological Class Histamine H2-receptor antagonist (H2-blocker)
General Purpose Gastric acid secretion inhibition
Origin Synthetic compound

Classification and Composition

Ranitidine Injection is a prescription-only medicine defined as a sterile aqueous solution for injection. The primary active component is ranitidine, typically present as ranitidine hydrochloride. This pharmaceutical is classified as a potent Histamine H2-receptor antagonist (H2-blocker), a class of synthetic compounds historically and clinically recognized for their efficacy in controlling gastric acid production. The drug is a single-ingredient product administered via the parenteral route, most often intravenously (IV) or intramuscularly (IM).

Mechanism Principle and General Purpose

The general therapeutic purpose of the injection is rooted in its ability to achieve gastric acid secretion inhibition. The ranitidine molecule works by physically blocking the H2-receptors on the stomach lining cells, thereby preventing signals that trigger acid release. This process significantly lowers the concentration of stomach acid, providing relief from irritation and discomfort associated with excessive acidity in the upper gastrointestinal tract. The solution for injection is distinguished by its capacity to deliver this acid-reducing effect rapidly and predictably when oral forms are not suitable or immediate intervention is necessary.

Regulatory References

  1. MedlinePlus, U.S. National Library of Medicine

What side effects are possible with Ranitidine Injection?

Official Side Effects and Safety Profile

The safety profile of Ranitidine Injection, as documented in regulatory sources such as the FDA and EMA SmPC, classifies potential adverse reactions based on their estimated frequency and the System-Organ Class affected. These classifications range from Uncommon to Very Rare.

Key Adverse Reactions by System

System-Organ Class Examples of Documented Reactions
Nervous System Headache, dizziness, malaise, reversible mental confusion, or hallucinations (Very Rare)
Gastrointestinal Constipation, diarrhea, nausea, vomiting, or acute pancreatitis (Rare)
Hepatobiliary Hepatitis (cholestatic, hepatocellular, or mixed), potentially leading to hepatic failure (Rare)
Blood/Lymphatic Leukopenia, thrombocytopenia (Rare), or severe effects like agranulocytosis and aplastic anemia (Very Rare)
Cardiac/Vascular Arrhythmias, including bradycardia and, rarely, asystole or hypotension

Serious Safety Considerations

The label specifies Serious Adverse Reactions which, though rare, represent significant risk. These include severe Hypersensitivity Reactions such as anaphylactic shock, rare Cardiac Arrhythmias, and severe Hepatobiliary Disorders.

Population and Exposure Notes

The safety documentation notes that certain effects, particularly CNS disturbances, may be reported more frequently in elderly patients or those with renal or hepatic impairment. Furthermore, Bradycardia has been associated with rapid intravenous administration, and specific patient groups (e.g., the elderly, those with chronic lung disease) have an increased officially noted risk of community-acquired pneumonia.

Safety Restrictions

Ranitidine Injection is contraindicated in individuals with known hypersensitivity to the medication. Official labeling also contains the necessary caution that a symptomatic response to treatment does not preclude the presence of underlying gastric malignancy.

Overdose and Emergency Response

Overdose: When to Seek Help

Official regulatory information describes overdose experience with Ranitidine Injection as limited, primarily resulting in transient adverse reactions when acute overdosage occurs.

Documented Clinical Manifestations of Overdose

Symptoms reported in regulatory documents following over-exposure or associated with high doses include effects on the central nervous system (CNS) and the cardiovascular system.

System Manifestations Described
Cardiovascular Bradycardia, A-V block, and asystole.
CNS Mental confusion and involuntary movement disorders (e.g., myoclonus, tremors).

Emergency Response and Management

In the event of suspected overdose, immediate contact with emergency medical services or a poison control center is necessary.

The official guidance for managing overdosage is to provide symptomatic and supportive therapy. No specific antidote is designated for ranitidine overdose; management focuses on addressing the specific clinical symptoms present and supporting vital functions.

Population-Specific Considerations

Reversible mental confusion and hallucinations have been reported in the general safety sections, predominantly affecting severely ill and elderly patients, suggesting this population may have heightened susceptibility to CNS effects even at therapeutic or slightly elevated exposures.

Therapeutic Uses of Ranitidine Injection

What Ranitidine Injection treats: main uses and benefits

Ranitidine injection is commonly used across conditions presenting with acute episodes. This therapeutic domain may be part of symptomatic management, as it is indicated for the treatment of duodenal ulcer, benign gastric ulcer, reflux esophagitis, post-operative peptic ulcer, Zollinger-Ellison Syndrome, and other conditions where reduction of gastric secretion and acid output is desirable. It may assist with managing symptoms that become more disruptive during flare-ups, such as those seen in reflux and peptic ulcer conditions.

Key Areas of Symptom Management

This medication is applied in clinical settings that involve acute or unstable symptom patterns, often concerning the pain and irritation caused by active ulcers (gastric and duodenal) and severe acid reflux episodes (reflux esophagitis). It is also relevant for easing the intense manifestations associated with symptoms related to systemic imbalance, such as those seen in hypersecretory conditions. The injection supports the patient during difficult episodes and assists with maintaining functional stability.

“It is used in settings where short-term symptom stabilization is important.”

Quick Fact: Relevant for Symptoms Related to Physical Discomfort

Summary of Indications

The medication is considered relevant for managing symptoms associated with duodenal ulcer, benign gastric ulcer, reflux esophagitis, post-operative peptic ulcer, and conditions like Zollinger-Ellison Syndrome. It helps address symptom clusters that may become intense or disruptive in these areas.

Regulatory References

  1. ZANTAC® (ranitidine hydrochloride) Tablets and Injection are indicated for the treatment of duodenal ulcer, benign gastric ulcer, reflux esophagitis, post-operative peptic ulcer, Zollinger-Ellison Syndrome, and other conditions where reduction of gastric secretion and acid output is desirable

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Ranitidine Injection

The eligibility for Ranitidine Injection is defined by governmental regulatory documents based on absolute prohibitions and restrictions related to a patient’s condition, age, and physiological status.

Classification Status & Eligible Age Groups
Populations Allowed Adults (18+ years) and Pediatric Patients (6 months and older) are the standard patient groups for use.
Populations Contraindicated Must not use if there is a known hypersensitivity to ranitidine or any component of the formulation, or a history of acute intermittent porphyria.
Classification Conditional Use and Restrictions
Organ Function Restriction Patients with impaired renal function (Creatinine Clearance < 50 mL/min) are eligible but require a mandatory dose adjustment.
Age Restriction Use is not recommended or generally not established in neonates (under 1 month of age).
Physiological Status Use during pregnancy or lactation is conditional and should occur only if considered essential by a physician.
Comorbidity Caution Caution is required in patients with predisposing factors for pneumonia or when gastric malignancy is suspected, as the drug may mask symptoms of the latter.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interactions with Ranitidine Injection are classified based on pharmacokinetic effects that alter the exposure of co-administered substances. The most significant interaction involves pH-dependent absorption interference. Ranitidine’s acid-reducing action can lower the bioavailability of medicines that require an acidic gastric environment for optimal absorption. This interference results in reduced plasma exposure for several oral agents, including tyrosine kinase inhibitors such as Dasatinib and Nilotinib. Due to this effect, co-administration with Pazopanib is formally classified as contraindicated by some regulatory authorities.

Another documented interaction is renal transporter competition. Ranitidine competes with certain substances, such as Procainamide, for excretion via renal tubular secretion. This competition leads to a measurable reduction in clearance for Procainamide, resulting in increased plasma concentrations of the co-administered drug.

Ranitidine is also a weak inhibitor of certain hepatic cytochrome P450 enzymes (e.g., CYP3A4). While the potential for clinically significant inhibition is generally considered low, this pathway may increase the exposure of select benzodiazepines, including Midazolam and Triazolam. A documented pharmacodynamic interaction exists with alcohol, where co-administration may lead to increased blood alcohol concentrations. Furthermore, official labels note a population-specific consideration: impaired renal function significantly alters the drug’s own pharmacokinetics, leading to increased Ranitidine plasma concentrations.

Mechanism of Action

Histamine H2 Receptor Competitive Antagonism

The core mechanism involves competitive antagonism at the Histamine H2 receptors ( H2R) located on the gastric parietal cells. By binding reversibly to this receptor, ranitidine blocks the natural agonist, histamine, from activating the primary signaling pathway for acid production.

⬇️ Interruption of the G s-Protein Signaling Cascade

This receptor blockade initiates an internal signaling interruption by preventing the H2R from activating adenylate cyclase, which lowers the cellular concentration of the second messenger cyclic AMP (cAMP). This targeted molecular event modifies the early steps that are required for stimulating the final acid-secreting enzyme.

️ Indirect Modulation of Gastric Acid Secretion

The resultant drop in cAMP reduces the energy and mobilization required to fully activate the H^+/ K^+-ATPase (Proton Pump). This mechanism leads directly to a physiological decrease in the volume and hydrogen ion ( H^+) concentration of HCl secreted into the stomach, thus modulating overall gastric secretion output.

Dosage and Administration Information

How to Use Ranitidine Injection

Ranitidine Injection is a sterile solution intended for use only via the parenteral route, which includes intramuscular (IM) injection or administration directly into a vein, known as intravenous (IV). The IV method may be implemented as a slow bolus, an intermittent infusion, or a continuous infusion. The general principle of its use is to deliver the medicine when oral administration is not possible or when a rapid and predictable effect is required in a hospital setting.

Official Dosing and Administration

The standard adult intermittent dose for IM or IV use is 50 mg, which is typically administered every 6 to 8 hours. The maximum recommended daily dose for this intermittent regimen is generally 400 mg. Continuous IV infusion is generally initiated at a rate of 6.25 mg/hour.

Administration Method Preparation & Rate Constraint
IM Injection No dilution is required.
IV Intermittent Bolus Dilute to no more than 2.5 mg/mL; inject over at least 5 minutes.
IV Intermittent Infusion Dilute to no more than 0.5 mg/mL; infuse over 15 to 20 minutes.

Population-Specific Dosing Rules

Official instructions mandate dose adjustments for patients with impaired renal function. For adults with a Creatinine Clearance (CrCl) less than 50 mL/min, the dosage frequency is typically reduced to 50 mg every 18 to 24 hours. In pediatric patients (6 months to 11 years), the maximum single dose is 50 mg every 6 to 8 hours. Furthermore, for patients undergoing hemodialysis, the official protocol states that the timing of the dose should coincide with the completion of the dialysis session.

Recent Clinical Evidence

Research evidence / Overview of studies for Ranitidine Injection

The evidence base for Ranitidine Injection is drawn from a variety of clinical research, including randomized controlled trials and specialized physiological studies. This overview describes the research that was studied for the use of the medicine, focusing only on the type of evidence available and the patterns that data show patterns related to different conditions, without providing any clinical guidance.

Evidence for Ulcer Healing and Prevention

Research for the injection was primarily focused on patients with duodenal and benign gastric ulcers. Studies examined the use of the medicine in both treating the active ulcer and in longer-term research examining the rate of ulcer recurrence.

Early research involved Randomized Controlled Trials (RCTs). These studies monitored outcomes such as endoscopic ulcer status and patient-reported outcomes describing perceived discomfort. The foundational evidence for this application is categorized as High in regulatory or authoritative reviews. Maintenance studies focused on outcomes related to ulcer recurrence during follow-up periods that could extend up to one year or longer.

Evidence for Severe Acid Hypersecretion

The injection was evaluated in patients with rare but pathological conditions known as hypersecretory conditions, such as Zollinger-Ellison Syndrome. Research focused on the parenteral delivery of the medicine in these specific clinical situations.

The studies conducted here were often specialized physiological function studies. Research examined physiological endpoints where changes were directly monitored. This included monitoring gastric acid output and measuring the resulting rise and maintenance of intragastric pH levels. The evidence level for this specialized application is also categorized as High in regulatory or authoritative reviews.

Key Limitations and Areas of Research Uncertainty

While the evidence base for Ranitidine Injection is substantial for its authorized uses, comparative evidence is lacking in modern large-scale trials against newer acid-suppressing agents, such as proton pump inhibitors (PPIs). Data for certain groups remain insufficient regarding long-term clinical outcomes in patients with specific chronic comorbidities. Furthermore, the follow-up durations were limited for acute interventions, and research provides context but does not determine whether an individual will respond similarly when compared to group patterns observed in studies.

Key Studies & References Product Monograph ZANTAC (Health Canada Regulatory Document)

Frequently Asked Questions (FAQ)

Common questions about Ranitidine Injection (FAQ)

Q: Is Ranitidine Injection the same as the ranitidine that was recalled?

Regulatory health authorities requested the withdrawal of all ranitidine products, including both oral tablets and the injectable form. This action was taken because an impurity called N-Nitrosodimethylamine (NDMA) was found to increase in concentration over time and when stored in certain conditions. For the most current status on specific ranitidine products, information from official sources is typically managed by a patient's healthcare team.

Q: What is the difference between Ranitidine Injection and famotidine injection (Pepcid)?

Both medicines belong to the same pharmacological class, known as Histamine H2 -receptor antagonists. They work by blocking the same type of receptor. However, official product information indicates they are eliminated from the body through different pathways. Research indicates that, by weight, famotidine may require a smaller dose to achieve similar acid-reducing effects.

Q: Is it normal to feel a stinging sensation where the Ranitidine Injection is given?

Official product documentation includes injection site reactions as part of the documented adverse reaction profile. This means that effects such as pain, burning, or stinging at the site where the injection is given are recognized as potential, though generally uncommon, reactions to the medicine.

Q: How quickly does the acid-reducing effect begin after receiving a Ranitidine Injection?

Clinical studies have shown that the medicine begins its acid-reducing effect very quickly. Following an intravenous injection, the ability to suppress stomach acid (raising the gastric pH above 4) can start within about 30 minutes. This rapid onset of action is consistent with its use when immediate intervention is needed in hospital settings.

Q: How long does the effect of a single Ranitidine Injection dose typically last?

Studies on how the body processes the medicine (pharmacokinetics) indicate that its elimination half-life is around 2.5 to 3 hours. This half-life supports the typical dosing schedule of every 6 to 8 hours, which is the interval typically applied in clinical settings to maintain acid suppression.

Q: What does it mean if my doctor mentions the 'Zantac' issue regarding Ranitidine?

Zantac was one of the common brand names for the medicine ranitidine. The 'issue' refers to the finding by regulatory agencies of an impurity called NDMA in the medicine, which led to a worldwide market withdrawal request for all ranitidine products.

Q: Why did the FDA issue warnings or statements about oral ranitidine?

The Food and Drug Administration (FDA) requested the removal of all ranitidine products from the market after a safety review. The FDA found that the impurity N-Nitrosodimethylamine (NDMA) in the product could increase over time, especially when stored at warmer temperatures. This increase could potentially expose consumers to unacceptable levels of the impurity.

Q: Is Ranitidine Injection used before or after certain types of surgery?

Official documentation indicates that the medicine is studied for use in clinical situations where there is a risk of stress ulcers. This is a condition that has been studied in patients who require supportive care, including care related to surgical procedures.

Q: Is it true that Ranitidine Injection is sometimes used to prevent stress ulcers?

The medicine is indicated for conditions related to stomach acid, and clinical research has focused on its use in ulcer healing and prevention. The injection is studied for use and applied in hospital settings for this purpose, particularly in high-risk situations.

Q: What should I tell my healthcare provider before receiving Ranitidine Injection?

Official product information highlights conditions that patients should discuss with their provider before administration. These include any known hypersensitivity to ranitidine, a history of acute intermittent porphyria, and conditions such as impaired kidney function or factors that might predispose a patient to pneumonia.

Q: Does Ranitidine Injection contain any common allergens or preservatives I should know about?

According to the official product description, the formulation may contain inactive ingredients like phenol. Phenol is sometimes used as a preservative. Information regarding sensitivities to inactive ingredients or preservatives can be reviewed by a patient’s healthcare team.

Q: Why are there different maximum doses of Ranitidine Injection for different conditions?

Dosing rules are defined based on the intended treatment goal. Conditions that cause extremely high acid production, such as pathological hypersecretory conditions, are addressed with different protocols than standard intermittent treatment. Continuous infusion protocols for certain rare, severe conditions allow for administration rates and total amounts that exceed those for standard intermittent treatment.

Q: What official sources recommend the use of Ranitidine Injection?

The use of this medicine is formally authorized and regulated by governmental bodies globally. These organizations include the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These and other regulatory bodies authorize and oversee the documented uses of the drug.

Q: Does Ranitidine Injection help with symptoms of GERD?

Yes, official labels indicate that ranitidine is used to treat conditions caused by excess stomach acid, which includes Gastroesophageal Reflux Disease (GERD). It is also approved for the related condition of erosive esophagitis (inflammation of the esophagus caused by acid).

Q: Can Ranitidine Injection be mixed with other medications in the same IV bag?

Official instructions specify that the medicine must be diluted with standard, compatible intravenous solutions before administration. Compatibility with other specific medications in the same IV bag or line is a complex question that is typically evaluated by a patient's hospital pharmacy staff.

Q: Is Ranitidine Injection used to treat a specific bacterial infection (like H. pylori)?

The medicine is classified as an H2 -receptor antagonist and works primarily by reducing stomach acid. Official labels do not list H. pylori infection as an indication for ranitidine used alone (monotherapy). H. pylori treatment typically requires a combination of medicines.

Q: Why would a doctor choose Ranitidine Injection over oral medication in an Intensive Care Unit (ICU)?

The injection is typically used in the ICU or similar settings when a patient cannot take medicine by mouth (the oral route), or when a rapid and reliably predictable reduction of stomach acid is necessary. Since it is administered intravenously or intramuscularly, it is a documented option when the oral route is not feasible.

Q: Does the evidence for Ranitidine Injection support its use in critical care patients?

The medicine has been evaluated in specialized physiological studies for patients with severe acid hypersecretion, a condition sometimes found in critical care. It is officially used to provide effective acid suppression in clinical situations where the oral route is not available, which commonly occurs in the critical care setting.

Q: If a patient is on a ventilator, can they still receive Ranitidine Injection?

Yes, because the medicine is administered via the parenteral route (intravenous or intramuscular), it bypasses the digestive system entirely. This route of delivery is a documented option for use in patients who are unable to take oral medication, such as those receiving respiratory support on a ventilator.

How should Ranitidine Injection be stored and disposed of?

How to Store and Dispose of Ranitidine Injection

Ranitidine Injection must be stored and handled according to specific regulatory requirements to maintain its integrity.

Storage Requirements

Store the injection at Controlled Room Temperature, typically between 20 C and 25 C. The product must be protected from light and should not be frozen.

Stability after Dilution: When mixed with standard intravenous solutions (e.g., 0.9% Sodium Chloride), the prepared solution is stable for up to 48 hours at room temperature. When mixed with TPN solutions, the stability limit is 24 hours.

Safety: Keep all unused product out of the reach and sight of children.

Disposal Instructions

Unused, expired, or unwanted Ranitidine Injection must be disposed of according to local regulations and established pharmaceutical waste procedures. Do not dispose of this medicine by flushing it down a toilet or pouring it down a drain, nor should it be placed in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Ranitidine Injection found in:

A-Z Index: